The proteomics market is estimated to reach USD 44.79 billion in 2025. It is anticipated to grow at a CAGR of 11.7% during the assessment period 2025 to 2035 and reach a value of USD 134.82 billion by 2035.
| Attributes | Description |
|---|---|
| Estimated Proteomics Market Size (2025E) | USD 44.79 billion |
| Projected Proteomics Market Value (2035F) | USD 134.82 billion |
| Value-based CAGR (2025 to 2035) | 11.7% |
| Aspect | Details |
|---|---|
| Definition | Proteomics is the study of proteins in organisms, focusing on their structure, activity, and total count. |
| Role of Mass Spectroscopy | Examines large proteomes (millions of cells) and single-cell samples effectively. |
| Healthcare Applications | Enables early disease detection, tailored treatments, and effective drug design for illnesses like cancer and diabetes. |
| Agriculture Applications | Improves crop quality, identifies proteins for stress and pest resistance, and predicts crop diseases for preventive care. |
| Benefits | Advances in technology simplify protein activity study and pathways analysis for targeted solutions. |
Personalized Medicine in Healthcare for Better Therapeutics to Foster Demand
For most diseases occurring in humans or plants, some proteins can malfunction or get hijacked, which might be causing the disease. Proteomics is essential for identifying the problem-causing protein. At the same time, how it is expressed and what structural changes are seen in it while the disease progresses can be studied. With proteomics, drug targets can be identified and how patients will respond to different drugs can be studied.
This helps in designing treatments and strategies to treat the disease in a targeted way. Proteomics, combined with precision medicine, is useful in doing precision studies in cancer. The complex process of cancer progression can be studied, and scientists can design drug targets for the diseases or disorders at a molecular level.
By identifying protein biomarkers, early diagnosis of diseases can be done. The study of how the disease progresses can be conducted, and researchers can get an idea of how to design treatments for different stages of the disease.
Proteomic’s Ability to Understand Metabolism of Medicines
With the help of proteomics, the absorption process of medicines can be understood. The mechanism of medicine breakdown in the body is understood by understanding which proteins are involved while the drug absorption is happening.
Work can be done to improve the effect of drugs and minimize the side effects of medicines. Scientists also get ideas about drug interactions so that a combination of drugs can be suggested to the patient to achieve the maximum effect and speed up a patient's recovery process.
Drugs can also show toxic effects at times, and this can be caused if there is any change in the protein expression caused after consumption of the drug. Hence, appropriate steps can be taken, and the research methodology can be altered to change the drug composition after the trials are conducted.
Growing Research Grants
Governments globally are investing in proteomics for precision medicine and advancements in the pharma industry. Apart from the government, private sector is helping the growth too. Several startups are working on developing advanced proteomic tools. Innovation is fast, and proteomics is also being applied in agriculture. Proteomics goes beyond these two applications of agriculture and healthcare, and even in environmental sciences, it is used.
By checking protein structure changes in microbial communities, it is possible to check environmental changes. Plant proteomes can be studied, and their yields can be improved. In healthcare, drug metabolism can be studied. Several mega projects, like the Human Proteome Project, where the entire protein content in a human can be mapped and studied, is also under progress.
High Costs Related to Proteomics May Hamper Demand
Although many applications of proteomics can be seen in different fields of research, the biggest restraint is cost issues. The procedures of carrying out the tests and experiments are quite cost consuming, and it might even require time to produce results. The equipment and instruments required to conduct the studies are also expensive.
The market is broadly divided into four major segments: by component type, technology, application, and end user.
Rising Number of Research Experiments to Increase Demand for Reagents & Kits
| Attributes | Details |
|---|---|
| Top Component Type | Reagents and Kits |
| Market Share in 2024 | 51.4% |
By component type, the market is divided into instruments, reagents & kits, and core proteomics services. The reagents & kits segment accounted for 51.4% of the market share in 2024.
Research and development are getting fueled because of the good funding that the government is providing. Reagents and kits are extremely important when carrying out research experiments and medical testing.
Processes such as the extraction of proteins, their purification, and further analysis need reagents and kits. The kits are often discarded after use, and new reagents and kits must be bought. Key manufacturers also compete with each other to produce high-quality reagents and kits worth the price paid by labs.
As proteomics research will boost, the demand for these kits and reagents will also increase. Manufacturers might focus on making reusable kits in the future if there are rising problems in waste management.
User-friendliness of Microarray Instruments to Generate Momentum
| Attributes | Details |
|---|---|
| Top Technology Type | Microarray instruments |
| Market Share in 2024 | 27.1% |
The market is divided into microarray instruments, X-ray crystallography, spectroscopy, chromatography, protein fractionation systems, electrophoresis, and surface plasma resonance systems. Among these, the microarray instruments segment accounted for 27.1% of the market share in 2024.
In proteomics, scientists usually conduct the simultaneous analysis of thousands of proteins on single microchip, called high throughput analysis. This is especially useful and ideal while studying a disease or developing a drug.
Microarray instruments are widely used for checking the expression of proteins to identify disease-causing proteins, check how proteins interact with each other, and even develop vaccines. When dealing with a large set of proteins to be studied and when time efficiency is important, microarray instruments help achieve faster processing times. Their designs are user-friendly, compact in size, and can be handled easily.
Growing Use of Proteomics in Drug Discovery to Generate Sales
The market is segmented by application into drug discovery, clinical diagnosis, and cancer research. In drug discovery, it is possible to easily identify the target for the drug if the protein profile is studied well. The drug action mechanism can be studied well. To find how effective the drug is, protein markers can be identified. It can also be studied if a drug is toxic in any way.
In clinical diagnosis, proteomics helps in detecting the disease-causing proteins. Diseases can also be differentiated based on their target proteins and attack methods. Patients can be monitored for protein changes taking place to know how they respond to the treatment. In cancer research, proteomics can be used for early cancer diagnosis, and focus can be put on targeted therapies.
Wide Usage of Proteomics in Various Institutions to Surge Demand
By end-user, the market is segmented into contract research organizations (CROs), research & academic institutions, and pharma & biotech companies. Governments of different countries are increasing their funding for research and development. Several research institutes host PhD, Post-doc, and master's students who work on thesis projects.
Hence, from an academic perspective, research and academic institutions show a demand for the market. Pharma and biotech companies are working tirelessly to develop effective medicines and drugs for specific diseases, and hence they also show a high demand for practicing proteomics.
| Country | CAGR (%) |
|---|---|
| USA | 7 |
| Canada | 12.1 |
| UK | 8.1 |
| Germany | 7 |
| France | 11.4 |
| China | 16.2 |
| Japan | 6.6 |
The USA shows a healthy market and is expected to grow at a CAGR of 7% during the forecast period. The USA is developed in terms of infrastructure, and the government is investing fairly well in research and development. In the USA, biotech and pharmaceutical companies are well developed.
The country's market might show a steady growth rate, and it might do more developments in personalized medicine. The National Institute of Health funds proteomics research heavily in the USA, further fueling market growth. Meanwhile, Canada is expected to grow at a CAGR of 12.1% during the forecast period.
The UK is poised to grow at a CAGR of 8.1% during the forecast period. The UK has carried out several initiatives in academic research, and the government funds these initiatives substantially. Biotech companies are seen to be working in collaboration with academic institutions. An example of a government initiative in the UK is the UK Biobank Project. This project focuses on multi-omics integration. The country is also increasing its investment in personalized medicine.
Apart from the UK, Germany is poised to grow at a CAGR of 7% during the study period. The biotech and pharmaceutical sectors are strong in Germany and they also get good funding. France is expected to grow at a CAGR of 11.4% during the assessment period, as the government supports many research projects.
China is expected to show a CAGR of 16.2% during the study period. Industrialization is taking place at a rapid pace in China, and the population is growing at a rapid pace too. Due to this, high expenditure on the healthcare industry can be seen. Domestic innovation and good funding from the Chinese government make the market grow faster than the Western countries.
Japan is expected to grow at a CAGR of 6.6% during the study period. The country has advanced technology and is focused on precision medicine.
The companies active in the market focus primarily on providing the best products, services, and results to ensure research progress. The companies mentioned below, drive the market forward by ensuring that the high demand for precision medicine is met. They also focus on biomarker discovery, and high-throughput proteomic solutions. This ensures a high market growth and also promotes innovation.
| Company | Area of Focus |
|---|---|
| Thermo Fisher Scientific Inc. | Mass spectroscopy instruments, reagents, and proteomic workflow kits. |
| Agilent Technologies | Liquid chromatography systems, bioinformatics tools, and targeted proteomics studies. |
| Danaher Corporation | Mass Spectroscopy solutions |
| GE Healthcare | Offering advanced protein purification systems |
| Bio-Rad Laboratories | Protein separation and analysis tools |
| Bruker Corporation | Spectrometry technologies for high-precision proteomic applications |
| Startup | Key Focus Area |
|---|---|
| Pixelgen Technologies | Single-cell spatial proteomics with Molecular Pixelation technology. |
| Alamar Biosciences | Precision proteomics for early disease detection using NULISA Platform and ARGO HT System. |
| Syncell | Subcellular protein purification and spatial proteomics analysis with the Microscoop platform. |
| Impact Proteomics | Advancing immune system proteomics for improved disease diagnostics and therapeutic interventions. |
| Cambrium | AI-designed lab-grown proteins for applications like skincare and other biotechnology solutions. |
The proteomics market is segmented by component types into instruments, reagents & kits, and core proteomics services.
By technology, the proteomics market is segmented into microarray instruments, x-ray crystallography, spectroscopy, chromatography, protein fractionation systems, electrophoresis, and surface plasma resonance systems.
The market is segmented by application into drug discovery, clinical diagnosis, and cancer research.
By end-user, the market is segmented into contract research organizations (cros), research & academic institutions, and pharma & biotech companies.
The market is predicted to reach a size of USD 134.82 billion by 2035.
The market is anticipated to be valued at USD 44.79 billion in 2025.
Some of the leading market players include Thermo Fisher Scientific Inc., Agilent Technologies, Danaher Corporation, and others.
The USA is a lucrative country for market players.
Explore Life Science & Biotechnology Insights
Proteomics Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
